7. May 12, 2019 4
MISSION STATEMENT
EVALUATION MATRIX
ORGANIZATION CUSTOMERS
PRODUCTS
SERVICES
MARKETS GROWTH TECHNOLOGY
PFIZER YES NO YES NO NO
ORGANIZATION SELF-CONCEPT
CONCERN FOR
PUBLIC IMAGE
PHILOSOPHY CONCERN FOR
EMPLOYEES
PFIZER NO YES NO NO
8. May 12, 2019 4
ANALYSIS OF CURRENT MISSION
AND VISION STATEMENT
►The current vision statement of Pfizer answers what the
company wants to become.
►It is concise and well put together in a single sentence.
►On the other hand, the company’s mission statement does
not articulate three essential components of a mission
statement which are the company’s concern;
for employees, technology, and the concern for its survival,
growth, and profitability
9. May 12, 2019 4
RECOMMENDATION FOR
MISSION STATEMENT
10. May 12, 2019 5
SWOT ANALYSIS
STRENGTH
Strong brand image.
Profitable pharmaceutical company.
Strong sales force.
Safe and effective drugs.
Global presence in all over the countries.
WEAKNESS
Expiring patents.
Low spending in R&D as compared to other
competitors.
Heavy reliance on blockbuster drugs.
Discontinued Projects related to vaccines.
OPPORTUNITIES
Technology advancement
Opportunities in Emerging markets
Merger and acquisition of Wyeth and Park Davis
expanded market share and penetration.
More drugs for chronic diseases.
THREATS
Regulatory approval of drugs.
Tax rate on medicines.
Development of patent drugs by other companies.
New product development by competitors.
13. May 12, 2019 4
COMPETITIVE PROFILE MATRIX
►The most important factor to being successful in the industry
is the Research and development as indicated by weight of
0.14.
►We can notice that Pfizer has the best market advertising,
customer service, store locations, financial profit and market
share but they were defeated in terms of research and
development which we note as the most important factor.
►Overall Pfizer is still the best among its competitors with a
score of 3.38 and Novartis as its strongest rival with 3.17
weighted score.
15. May 12, 2019 6
EXTERNAL FACTOR
EVALUATION (EFE) MATRIX
16. May 12, 2019 6
EXTERNAL FACTOR
EVALUATION (EFE) MATRIX
17. May 12, 2019 4
RESULTS OF EFE MATRIX
►The table illustrated above shows that Pfizer got a total
weighted score of 2.88 for its External Factor Evaluation (EFE)
matrix which shows an above average response to its existing
opportunities and threats in the industry.
►The current strategies that the company is using is
satisfactory, but these will need to be improved for Pfizer to keep
the top position among its competitors.
19. May 12, 2019 6
INTERNAL FACTOR
EVALUATION (IFE) MATRIX
20. May 12, 2019 6
INTERNAL FACTOR
EVALUATION (IFE) MATRIX
21. May 12, 2019 4
RESULTS OF IFE MATRIX
►The table illustrated above shows that Pfizer
got a total weighted score of 3.06 for its
Internal Factor Evaluation matrix.
►This shows an above average response to its
existing Strengths and weaknesses inside the
company.
►Pfizer tries its best to capitalize on its
strengths and eliminate its weaknesses.
40. BCG MATRIX
May 12, 2019 6
►It can be observed from this graph that Pharmaceutical products are the
stars of the company while its Animal Health and Corporate are its cash
cows.
►Pharmaceuticals, being the company’s star, has a large market share
and shows the greatest potential for growth among other divisions.
►The other segments, while having large market shares, show low levels
of growth.
►The pie slices within the circles also reveals the percent of corporate
profits contributed by each division.
►This shows that Pharmaceuticals contributed most profits, with Animal
Health in second.
42. May 12, 2019 6
QUANTITATIVE STRATEGIC
PLANNING MATRIX (QSPM)
43. May 12, 2019 6
Key Factors
Increase
R&D funds
to increase
probability of
developing
new product
Market
Development
specifically on
Emerging
Markets
(China,India)
Acquisition
of Wyeth
Opportunities Weight AS TAS AS TAS AS TAS
1
Strategic agreements with other
pharmaceutical companies and orgs to
boost its research.
0.09 4 0.36 1 0.09 3 0.27
2
Increasing awareness about healthcare
needs
0.06 3 0.18 3 0.18 2 0.12
3
Global Penetration through mergers
and acquistions
0.07 3 0.21 2 0.14 4 0.28
4
Increasing demand for quality healthcare
solotions
0.07 2 0.14 3 0.21 3 0.21
5
Restructuring strategy designed to cut
costs and leaner company
0.03 3 0.09 3 0.09 4 0.12
6
Funding available to facilitate
product/company
0.02 4 0.08 3 0.06 4 0.08
7
Acquisitions (Wyeth) and in-licensing/
co-development opportunities
0.07 3 0.21 3 0.21 4 0.28
8 Expansion into biologies market 0.05 2 0.1 3 15 3 0.15
9 E-Commerce 0.03 2 0.06 2 0.06 2 0.06
10
High profits, revenues and funds are
available to uplift the company'sprogress
0.04 2 0.08 3 0.12 3 0.12
